Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Up ∞ in May

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the target of a large growth in short interest in May. As of May 15th, there was short interest totaling 17,114 shares, a growth of ∞ from the April 30th total of 0 shares. Based on an average daily trading volume, of 28,945 shares, the short-interest ratio is presently 0.6 days. Approximately 0.0% of the shares of the stock are sold short.

Inhibitor Therapeutics Price Performance

Shares of INTI stock traded down $0.00 during mid-day trading on Tuesday, hitting $0.08. The company had a trading volume of 1,242 shares, compared to its average volume of 37,422. Inhibitor Therapeutics has a 52-week low of $0.04 and a 52-week high of $0.12. The stock’s 50 day moving average price is $0.09 and its 200-day moving average price is $0.07. The company has a market capitalization of $14.43 million, a P/E ratio of -8.35 and a beta of -0.58.

Inhibitor Therapeutics (OTCMKTS:INTI) last released its earnings results on Friday, May 15th. The company reported $999.00 EPS for the quarter.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.